Blood:采用CD19/CD20 CAR T细胞治疗难治性/复发性非霍奇金淋巴瘤

2020-06-22 QQY MedSci原创

TanCAR7 T细胞显示出广泛的抗原覆盖范围,并形成了优越的IS结构,这可能与其强大的抗肿瘤活性有关;在r/rNHL患者中,TanCAR7 T细胞可引起有效而持久的抗肿瘤反应,且无≥3级的CRES。

靶向CD19的嵌合抗原受体T(CAR T)细胞在血液系统恶性肿瘤(如复发/难治性非霍奇金淋巴瘤,r/rNHL)的治疗中取得了突破;但是,CAR T细胞治疗后高失败率和复发率是要克服的重大障碍。

在本研究中, 研究人员设计了一些列的串联CAR(TanCAR),发现这些TanCAR T细胞不仅表现出了CD19和CD20的双重抗原靶向,还显示出优越的稳定的免疫突触(IS)结构,这可能与其强大的抗肿瘤活性有关。

在开放的单臂的I/IIa期试验(NCT03097770)中,研究人员招募了33位r/rNHL患者,其中28位在条件化疗后输注了TanCAR T细胞。主要目的是评估TanCAR T细胞的安全性和耐受性。次要目的是评估疗效、无进展存活期和总体存活率。

14位(50%)患者发生细胞因子释放综合征(CRS),其中36%的患者为1级或2级,14%的患者为3级。无3级及以上的CAR T细胞相关脑病综合征(CRES) 发生。一位患者死于治疗相关的重度肺部感染

总体缓解率为79%,完全缓解率为71%。12个月时的无进展存活率为64%。

在本研究中,TanCAR7 T细胞用于r/rNHL患者引起有效且持久的抗肿瘤反应,且无3级及以上的CRES发生。

原始出处:

Chuan Tong,et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma. Blood. June 18,2020

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1909825, encodeId=76ba190982530, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed May 26 07:20:45 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943809, encodeId=f1461943809d9, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4287, encryptionId=44ca428e60, topicName=CD20)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Mon Dec 07 03:20:45 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805649, encodeId=3f9b80564964, content=相当不错的方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLajLoBBBPgMHaHLqrxnjLrmPgqMF9XqXMaqtzG5XIn5icichY4CpV91bO7H4SXZ8NYf69su3YNTPcw/132, createdBy=158b2571614, createdName=asheng007586, createdTime=Sat Aug 01 19:35:50 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416462, encodeId=a942141646285, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4279, encryptionId=924442e98f, topicName=CD19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1583186918, createdName=dingxiaobo, createdTime=Wed Jun 24 09:20:45 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528668, encodeId=f14f15286689e, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Jun 24 09:20:45 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799402, encodeId=a56fe99402a6, content=<a href='/topic/show?id=0d3240e64e' target=_blank style='color:#2F92EE;'>#CAR-T细胞治疗#</a>双靶点CAR-T又突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4076, encryptionId=0d3240e64e, topicName=CAR-T细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jun 22 20:23:34 CST 2020, time=2020-06-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1909825, encodeId=76ba190982530, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed May 26 07:20:45 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943809, encodeId=f1461943809d9, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4287, encryptionId=44ca428e60, topicName=CD20)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Mon Dec 07 03:20:45 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805649, encodeId=3f9b80564964, content=相当不错的方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLajLoBBBPgMHaHLqrxnjLrmPgqMF9XqXMaqtzG5XIn5icichY4CpV91bO7H4SXZ8NYf69su3YNTPcw/132, createdBy=158b2571614, createdName=asheng007586, createdTime=Sat Aug 01 19:35:50 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416462, encodeId=a942141646285, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4279, encryptionId=924442e98f, topicName=CD19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1583186918, createdName=dingxiaobo, createdTime=Wed Jun 24 09:20:45 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528668, encodeId=f14f15286689e, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Jun 24 09:20:45 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799402, encodeId=a56fe99402a6, content=<a href='/topic/show?id=0d3240e64e' target=_blank style='color:#2F92EE;'>#CAR-T细胞治疗#</a>双靶点CAR-T又突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4076, encryptionId=0d3240e64e, topicName=CAR-T细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jun 22 20:23:34 CST 2020, time=2020-06-22, status=1, ipAttribution=)]
    2020-12-07 aliceclz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1909825, encodeId=76ba190982530, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed May 26 07:20:45 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943809, encodeId=f1461943809d9, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4287, encryptionId=44ca428e60, topicName=CD20)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Mon Dec 07 03:20:45 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805649, encodeId=3f9b80564964, content=相当不错的方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLajLoBBBPgMHaHLqrxnjLrmPgqMF9XqXMaqtzG5XIn5icichY4CpV91bO7H4SXZ8NYf69su3YNTPcw/132, createdBy=158b2571614, createdName=asheng007586, createdTime=Sat Aug 01 19:35:50 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416462, encodeId=a942141646285, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4279, encryptionId=924442e98f, topicName=CD19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1583186918, createdName=dingxiaobo, createdTime=Wed Jun 24 09:20:45 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528668, encodeId=f14f15286689e, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Jun 24 09:20:45 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799402, encodeId=a56fe99402a6, content=<a href='/topic/show?id=0d3240e64e' target=_blank style='color:#2F92EE;'>#CAR-T细胞治疗#</a>双靶点CAR-T又突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4076, encryptionId=0d3240e64e, topicName=CAR-T细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jun 22 20:23:34 CST 2020, time=2020-06-22, status=1, ipAttribution=)]
    2020-08-01 asheng007586

    相当不错的方法

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1909825, encodeId=76ba190982530, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed May 26 07:20:45 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943809, encodeId=f1461943809d9, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4287, encryptionId=44ca428e60, topicName=CD20)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Mon Dec 07 03:20:45 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805649, encodeId=3f9b80564964, content=相当不错的方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLajLoBBBPgMHaHLqrxnjLrmPgqMF9XqXMaqtzG5XIn5icichY4CpV91bO7H4SXZ8NYf69su3YNTPcw/132, createdBy=158b2571614, createdName=asheng007586, createdTime=Sat Aug 01 19:35:50 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416462, encodeId=a942141646285, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4279, encryptionId=924442e98f, topicName=CD19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1583186918, createdName=dingxiaobo, createdTime=Wed Jun 24 09:20:45 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528668, encodeId=f14f15286689e, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Jun 24 09:20:45 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799402, encodeId=a56fe99402a6, content=<a href='/topic/show?id=0d3240e64e' target=_blank style='color:#2F92EE;'>#CAR-T细胞治疗#</a>双靶点CAR-T又突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4076, encryptionId=0d3240e64e, topicName=CAR-T细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jun 22 20:23:34 CST 2020, time=2020-06-22, status=1, ipAttribution=)]
    2020-06-24 dingxiaobo
  5. [GetPortalCommentsPageByObjectIdResponse(id=1909825, encodeId=76ba190982530, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed May 26 07:20:45 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943809, encodeId=f1461943809d9, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4287, encryptionId=44ca428e60, topicName=CD20)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Mon Dec 07 03:20:45 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805649, encodeId=3f9b80564964, content=相当不错的方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLajLoBBBPgMHaHLqrxnjLrmPgqMF9XqXMaqtzG5XIn5icichY4CpV91bO7H4SXZ8NYf69su3YNTPcw/132, createdBy=158b2571614, createdName=asheng007586, createdTime=Sat Aug 01 19:35:50 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416462, encodeId=a942141646285, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4279, encryptionId=924442e98f, topicName=CD19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1583186918, createdName=dingxiaobo, createdTime=Wed Jun 24 09:20:45 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528668, encodeId=f14f15286689e, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Jun 24 09:20:45 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799402, encodeId=a56fe99402a6, content=<a href='/topic/show?id=0d3240e64e' target=_blank style='color:#2F92EE;'>#CAR-T细胞治疗#</a>双靶点CAR-T又突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4076, encryptionId=0d3240e64e, topicName=CAR-T细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jun 22 20:23:34 CST 2020, time=2020-06-22, status=1, ipAttribution=)]
    2020-06-24 freve
  6. [GetPortalCommentsPageByObjectIdResponse(id=1909825, encodeId=76ba190982530, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed May 26 07:20:45 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943809, encodeId=f1461943809d9, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4287, encryptionId=44ca428e60, topicName=CD20)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Mon Dec 07 03:20:45 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805649, encodeId=3f9b80564964, content=相当不错的方法, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLajLoBBBPgMHaHLqrxnjLrmPgqMF9XqXMaqtzG5XIn5icichY4CpV91bO7H4SXZ8NYf69su3YNTPcw/132, createdBy=158b2571614, createdName=asheng007586, createdTime=Sat Aug 01 19:35:50 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416462, encodeId=a942141646285, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4279, encryptionId=924442e98f, topicName=CD19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1583186918, createdName=dingxiaobo, createdTime=Wed Jun 24 09:20:45 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528668, encodeId=f14f15286689e, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Jun 24 09:20:45 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799402, encodeId=a56fe99402a6, content=<a href='/topic/show?id=0d3240e64e' target=_blank style='color:#2F92EE;'>#CAR-T细胞治疗#</a>双靶点CAR-T又突破, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4076, encryptionId=0d3240e64e, topicName=CAR-T细胞治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Jun 22 20:23:34 CST 2020, time=2020-06-22, status=1, ipAttribution=)]
    2020-06-22 lovetcm

    #CAR-T细胞治疗#双靶点CAR-T又突破

    0

相关资讯

2018 专家共识:儿童接受嵌合抗原受体T细胞治疗管理指南

2017年,嵌合抗原受体(CAR)T细胞治疗儿童和青少年复发性和/或难治性CD19+的急性淋巴细胞白血病患者,成果美国首个获批的基因疗法。本文主要针对儿童接受CAR-T细胞治疗的相关内容提供指导建议。